Adding Tafasitamab and Lenalidomide to R-CHOP Improves PFS in Patients with Previously Untreated High-Intermediate- or High-Risk DLBCL or HGBL By Ogkologos - June 9, 2026 45 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the frontMIND study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR “Selfless and Incredible” Mother Leaves Behind Five Children After Battling Breast... November 25, 2020 Insulin Resistance May Contribute to Poorer Breast Cancer Outcomes, Study Says June 2, 2020 Research with integrity – referencing work is way more than just... May 3, 2023 Bride Learns Sign Language, Surprises Groom’s Deaf Parents & Signs Her... January 11, 2022 Load more HOT NEWS Could proton beam therapy improve throat cancer treatment? Julia Louis-Dreyfus Talks About The Side Effects of Chemotherapy Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... VA Study Finds No Disparities in Prostate Cancer Deaths with Equal...
